Skip to content

KYNTRA BIO, INC.

KYNB

CIK 0000921299 · Pharmaceutical Preparations · Nasdaq

  • FIBROGEN INC (until 2026-01-07)
← back to feed
Revenue (TTM)
$8.9M
−78.3% YoY Q1 Apr 2026
Net Income (TTM)
$182.47M
+485.6% YoY Q1 Apr 2026
EPS Diluted (TTM)
$45.12
+481.6% YoY Q1 Apr 2026
Gross Margin
50.7%
Q1 Apr 2026
Operating Margin
-519.1%
Q1 Apr 2026
Net Margin
2,050.0%
Q1 Apr 2026
Free Cash Flow (TTM)
−$172.68M
Q1 Apr 2026
Cash
$37M
Q1 Apr 2026
Total Debt
$75M
Q1 Apr 2026
Shares Outstanding
4.05M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings